Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity
John R Power,Charles Dolladille,Adriel Procureur,Stephane R Ederhy,Nicolas L Palaskas,Lorenz H Lehmann,Jennifer Cautela,Pierre-Yves Courand,Salim S Hayek,Han Zhu,Vlad G Zaha,Richard K Cheng,Joachim Alexandre,Francois Roubille,Lauren A Baldassarre,Alan H Baik,Michal Laufer-Perl,Yuichi Tamura,Aarti Asnani,Sanjeev Francis,Elizabeth M Gaughan,Peter P Rainer,Guillaume Bailly,Danette Flint,Dimitri Arangalage,Eve Cariou,Roberta Florido,Anna Narezkina,Yan Liu,Shahneen Sandhu,Darryl Leong,Nahema Issa,Nicolas Piriou,Lucie Heinzerling,Giovanni Peretto,Shanthini M Crusz,Nausheen Akhter,Joshua E Levenson,Isik Turker,Assie Eslami,Charlotte Fenioux,Pedro Moliner,Michel Obeid,Wei-Ting Chang,Stephen M Ewer,Seyed Ebrahim Kassaian,International ICI-Myocarditis Registry,Douglas B Johnson,Anju Nohria,Osnat Itzhaki Ben Zadok,Javid J Moslehi,Joe-Elie Salem
DOI: https://doi.org/10.1101/2024.06.02.24308336
2024-06-03
Abstract:Background: Immune-checkpoint inhibitors (ICI) are associated with life-threatening myocarditis but milder presentations are increasingly recognized. The same autoimmune process that causes ICI-myocarditis can manifest concurrent generalized myositis, myasthenia-like syndrome, and respiratory muscle failure. Prognostic factors for this 'cardiomyotoxicity' are lacking.
Methods: A multicenter registry collected data retrospectively from 17 countries between 2014-2023. A multivariable cox regression model (hazard-ratio(HR), [95%confidence-interval]) was used to determine risk factors for the primary composite outcome: severe arrhythmia, heart failure, respiratory muscle failure, and/or cardiomyotoxicity-related death. Covariates included demographics, comorbidities, cardio-muscular symptoms, diagnostics, and treatments. Time-dependent covariates were used and missing data were imputed. A point-based prognostic risk score was derived and externally validated.
Results: In 748 patients (67% male, age 23-94), 30-days incidence of the primary composite outcome, cardiomyotoxic death, and overall death were 33%, 13%, and 17% respectively. By multivariable analysis, the primary composite outcome was associated with active thymoma (HR=3.60[1.93-6.72]), presence of cardio-muscular symptoms (HR=2.60 [1.58-4.28]), low QRS-voltage on presenting electrocardiogram (HR for ≤0.5mV versus >1mV=2.08[1.31-3.30]), left ventricular ejection fraction (LVEF) <50% (HR=1.78[1.22-2.60]), and incremental troponin elevation (HR=1.86 [1.44-2.39], 2.99[1.91-4.65], 4.80[2.54-9.08], for 20, 200 and 2000-fold above upper reference limit, respectively). A prognostic risk score developed using these parameters showed good performance; 30-days primary outcome incidence increased gradually from 3.9%(risk-score=0) to 81.3%(risk-score=4). This risk-score was externally validated in two independent French and US cohorts. This risk score was used prospectively in the external French cohort to identify low risk patients who were managed with no immunosuppression resulting in no cardio-myotoxic events.
Conclusions: ICI-myocarditis can manifest with high morbidity and mortality. Myocarditis severity is associated with magnitude of troponin, thymoma, low-QRS voltage, depressed LVEF, and cardio-muscular symptoms. A risk-score incorporating these features performed well.